8-K
filed March 15, 2024, 7:59 PM ET
CIK 0001832415
other material
confidence high
sentiment negative
materiality 1.00
Better Therapeutics voluntarily delists from Nasdaq, entire board and top officers replaced by wind-down specialist
Better Therapeutics, Inc.
- Nasdaq hearing March 14 led to voluntary delisting; trading suspended March 18, 2024.
- All seven directors resigned, including Chairman Frank Karbe, and CEO Karbe stepped down.
- CMO Dr. Mark Berman and CPO Kristyn Wynholds terminated from positions.
- Craig R. Jalbert appointed sole officer and director; annual compensation $33,333.
- Company intends to file Form 15 to suspend SEC reporting obligations.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Risa Lavizzo-Mourey resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Richard Carmona resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kristyn Wynholds was terminated as Chief Product Officer at Better Therapeutics, Inc..
- Action
- terminated
- Role
- Chief Product Officer
Exact text from the filing
On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Geoffrey Parker resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Mark Berman was terminated as Chief Medical Officer at Better Therapeutics, Inc..
- Action
- terminated
- Role
- Chief Medical Officer
Exact text from the filing
On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Armanino resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig R. Jalbert was appointed as Director at Better Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank Karbe resigned as CEO, President, Treasurer and Secretary at Better Therapeutics, Inc..
- Action
- resigned
- Role
- CEO, President, Treasurer and Secretary
Exact text from the filing
On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Perry resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Elder Granger resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig R. Jalbert was appointed as CEO, President, Treasurer, Secretary at Better Therapeutics, Inc..
- Action
- appointed
- Role
- CEO, President, Treasurer, Secretary
Exact text from the filing
On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank Karbe resigned as Director at Better Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.